AI voice dictation that's actually intelligent

Typeless turns your raw, unfiltered voice into beautifully polished writing - in real time.

It works like magic, feels like cheating, and allows your thoughts to flow more freely than ever before.

Your voice is your strength. Typeless turns it into a superpower.

Download for Mac today

Now you can tell ChatGPT to hack with limits

HexStrike AI just linked ChatGPT, Claude, and Copilot to 150+ real security tools. This isn’t a demo. It’s live, modular, and made for red teams and security pros.

Here’s everything you need to know:

• HexStrike AI v6.0 now integrates directly with leading AI models using a multi-agent protocol.

• Security teams can issue natural-language commands to run automated assessments across networks, APIs, apps, and more.

• Under the hood, it triggers coordinated actions using tools like Nmap, Nuclei, Amass, and even custom exploit generators.

• Users see everything unfold via live dashboards with color-coded vulnerabilities and CVSS scores.

• Efficiency gains are dramatic: tasks that once took hours or days now take minutes.

• Built-in safeguards like Safe Mode and audit logs ensure authorized use within compliance boundaries.

• The goal: democratize elite-level cybersecurity through automation and AI orchestration.

This is the future of cybersecurity where knowing how to phrase a prompt might matter more than knowing how to run a scan. It’s powerful, but it raises big questions: Who gets access? And how do we balance speed with oversight?

While Wall Street backed away, Cathie Wood dropped $12 million

Cathie Wood has made a career betting early on disruptive tech. Her latest move? Buying a collapsing AI stock right as others are getting out.

Here’s everything you need to know:

• On August 15, Wood’s ARK fund bought $12 million worth of CoreWeave after a steep two-day drop.

• The stock fell over 36% following weak earnings and surging operational costs.

• CoreWeave builds AI infrastructure using GPU-accelerated computing, a space booming with demand.

• Despite posting a wider-than-expected Q2 loss, revenue jumped 207% and guidance was slightly above estimates.

• Ark’s flagship fund (ARKK) is up 33.7% YTD, despite a volatile ride and long-term underperformance.

• Wood’s strategy: buy high-volatility, high-upside tech during weakness and hold for the rebound.

• While she’s buying, big banks like JPMorgan and Morgan Stanley are helping arrange sales of up to $10B in CoreWeave shares.

Cathie Wood’s strategy isn’t about timing the market, it’s about conviction when others hesitate. Whether CoreWeave rebounds or not, this is the kind of asymmetric bet that defines her playbook. The question is: Would you buy when everyone else is selling?

Good enough” AI doesn’t cut it in healthcare

In most industries, a small error is inconvenient. In healthcare, it can cost lives. And general-purpose AI models including GPT-4 aren’t built for that kind of pressure.

Here’s everything you need to know:

• General AI models update behind the scenes, making them unreliable for regulated clinical environments.

• GPT-4 can sound confident while being wrong, a dangerous combo in patient care.

• These models lack deep domain knowledge, often misreading nuance in clinical text or radiology reports.

• Even top models only match or trail purpose-built medical AI in diagnostic accuracy.

• Specialized models trained on real clinical data consistently perform better in narrow healthcare use cases.

• Purpose-built tools are more auditable, easier to monitor, and safer to deploy.

• GPT might be great for drafting education content but not for diagnosing a rare cardiac condition.

This isn’t about hating on general AI. It’s about respecting the stakes. If your tool might hallucinate or shift behavior without notice, it has no place making clinical decisions. “Good enough” works for chatbots. For patients, only purpose-built, transparent AI will do.

Thanks for reading…

That’s a wrap.

What's on your mind?

Share your best ideas with us at theprohumanai@gmail. com

We'll bring your ideas to life. Send them our way, and we'll get to work on making them a reality.